Inflammation within the skin causes hyperproliferation of keratinocytes, and results in skin scaling and thickening, itching and erythema (Baliwag et al., 2015). Patients with psoriasis are also at an increased risk of several comorbidities, including cardiovascular and metabolic diseases, with psoriasis frequently having a profoundly negative effect on patients’ quality of life (Feldman et al, 2015; Menter et al, 2008).
Take a look through the IL-17 and psoriasis Learning Zone as we focus on the role of IL-17 family in psoriasis pathophysiology and review how disease severity is assessed and how modern biologics allow us to aim higher and target complete skin clearance. Also, explore the key clinical trial data for anti-IL-17 biologics in psoriasis and find out what the experts think of them.
Targeting IL-17 to treat psoriasis
IL-17 plays a central role in the psoriatic inflammatory process. Discover the mechanism of action of the different biologics targeting the IL-17 pathway.
Aiming for PASI 100
What should be the goal of psoriasis treatment? This section of the Learning Zone describes the importance of aiming for complete skin clearance when treating psoriasis. Recent advances in biologic treatments are making this aim achievable.
This content has been developed in collaboration with LEO Pharma A/S who provided some of the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.